Interferon γ-Inducible Protein 10: A Predictive Marker of Successful Treatment Response in Hepatitis C Virus/HIV-Coinfected Patients

Background:Elevated pretreatment interferon (IFN) γ-inducible protein 10 (IP-10/CXCL10) levels are a marker of treatment nonresponse in hepatitis C virus (HCV)-monoinfected patients. We undertook this study to determine if IP-10 is a marker of treatment outcome in HCV/HIV-coinfected patients. Methods:Nineteen HCV/HIV-coinfected patients were treated with weight-based pegylated (PEG) IFNα-2b (1.5 μg/kg) once weekly plus weight-based ribavirin (1000 or 1200 mg) daily for up to 48 weeks. Plasma IP-10, monokine induced by IFNγ/CXCL9 (Mig), and IFN-inducible T-cell α-chemoattractant/CXCL11 (I-TAC) levels were measured by enzyme-linked immunosorbent assay on samples obtained frequently during the first 3 PEG-IFN doses and throughout treatment. Results:Median pretreatment plasma IP-10 (interquartile range [IQR]) levels were significantly lower in virological responders (n = 6) at 217 (IQR: 181-301) pg/mL compared with nonresponders (n = 13) at 900 (IQR: 628-2048) pg/mL (P = 0.002), whereas pretreatment Mig and I-TAC levels did not differ significantly. Plasma IP-10 levels of 400 pg/mL before treatment and on days 7 and 14 could be used to identify likely coinfected PEG-IFN/ribavirin nonresponders. PEG-IFN-induced elevations in IP-10 were greater in virological responders than in nonresponders (∼10-fold vs. ∼4-fold) after the first PEG-IFN dose. Conclusions:IP-10 may be a biomarker of HCV treatment outcome in difficult-to-treat HCV/HIV-coinfected patients.

• Publication year

  2007

• Venue

  JAIDS Journal of Acquired Immune Deficiency Syndromes

• Publication date

  2007-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/QAI.0b013e3180559219
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection

  2007cited by this paper
• Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race

  2006cited by this paper
• Genomic response to interferon‐α in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics

  2006cited by this paper
• IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection

  2006cited by this paper
• Pharmacodynamics of PEG‐IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders

  2006cited by this paper
• Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.

  2006cited by this paper
• Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C.

  2005cited by this paper
• Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

  2005cited by this paper
• Roles for CXC Chemokine Ligands 10 and 11 in Recruiting CD4+ T Cells to HIV-1-Infected Monocyte-Derived Macrophages, Dendritic Cells, and Lymph Nodes1

  2005cited by this paper
• Association of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C

  2005cited by this paper
• Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

  2004cited by this paper
• Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

  2004cited by this paper
• CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Metaanalysis of 3 Vanguard Studies

  2004cited by this paper
• Increased circulating and intrahepatic T‐cell‐specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy

  2004cited by this paper
• Expression of the chemokine IP‐10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation

  2003cited by this paper
• Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

  2002cited by this paper
• Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease

  2002cited by this paper
• Numerical recipes in C

  2002cited by this paper
• Increasing Impact of Chronic Viral Hepatitis on Hospital Admissions and Mortality among HIV-Infected Patients

  2001cited by this paper
• Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.

  2001cited by this paper
• Elevated Levels of Interleukin-8 in Serum Are Associated with Hepatitis C Virus Infection and Resistance to Interferon Therapy

  2001cited by this paper
• Effect of HIV‐1 Infection on Lymphocyte Proliferation in Gut‐Associated Lymphoid Tissue

  2001cited by this paper
• Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection.

  2001cited by this paper
• Increasing Cerebrospinal Fluid Chemokine Concentrations Despite Undetectable Cerebrospinal Fluid HIV RNA in HIV‐1‐Infected Patients Receiving Antiretroviral Therapy

  2000cited by this paper
• Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data

  2000cited by this paper
• Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver.

  1999cited by this paper
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

  1998cited by this paper
• Endogenous interferon-alpha concentration and outcome of interferon treatment in patients with chronic hepatitis C.

  1997influential reference
• Endogenous Interferon-α Concentration and Outcome of Interferon Treatment in Patients with Chronic Hepatitis C

  1997cited by this paper
• Classification of chronic viral hepatitis: a need for reassessment.

  1991cited by this paper
• Analysis of serial measurements in medical research.

  1990cited by this paper
• Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction.

  1986cited by this paper

• Intrahepatic Viral Kinetics during Direct-Acting Antivirals for Hepatitis C in HIV Co-infection:The ACTG A5335S Substudy.

  2020cites this paper
• Peripheral TNFα elevations in abstinent alcoholics are associated with hepatitis C infection

  2018cites this paper
• Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology

  2017cites this paper
• Coinfection with Hepatitis C Virus among HIV-1-Infected Individuals Increases Proinflammatory Cytokines and HIV-1 Disease Severity

  2016cites this paper
• Toll-like Receptor Expression and Signaling in Peripheral Blood Mononuclear Cells Correlate With Clinical Outcomes in Acute Hepatitis C Virus Infection.

  2016cites this paper
• Inflammatory molecules expression pattern for identifying pathogen species in febrile patient serum.

  2016cites this paper
• Chemokine IP-10 is correlated with cardiac responses and status of infection with HIV and HCV in methadone maintenance patients.

  2015cites this paper
• CXCR3 ligands in disease and therapy.

  2015cites this paper
• Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible-Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China

  2015cites this paper
• Single Nucleotide Polymorphisms of CXCL9-11 Chemokines Are Associated With Liver Fibrosis in HIV/HCV-Coinfected Patients

  2015cites this paper
• Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin.

  2015cites this paper
• CRP and CD 4 + t-cell immune activation associated with HIV clinical progression in a multinational case-cohort study

  2015cites this paper
• Enhancing T-cell responses to vaccination of HIV-1 infected subjects on antiretroviral therapy

  2014cites this paper
• IP-10 in chronic hepatitis C patients treated with high-dose interferon.

  2014cites this paper
• Predictors of the therapeutic response in hepatitis C. A 2013 update.

  2014cites this paper
• Serum interferon‐gamma‐inducible protein‐10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C

  2014cites this paper
• Title Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection : Implications for the innate immune response Permalink

  2014influential citation
• Immunosensors using metallic nanoparticle-based signal enhancement for bacterial detection and tuberculosis diagnosis

  2014cites this paper
• Chemokine Deregulation in HIV Infection: Role of Interferon Gamma Induced Th1-Chemokine Signaling

  2013cites this paper
• IL28B Polymorphism, Pretreatment CXCL10, and HCV RNA Levels Predict Treatment Response in Racially Diverse HIV/HCV Coinfected and HCV Monoinfected Patients

  2013cites this paper
• CXC chemokine IP-10: a key actor in liver disease?

  2013cites this paper
• Relationship of interferon-&ggr;-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4

  2013cites this paper
• Plasma interferon-gamma-inducible protein 10 can be used to predict viral load in HIV-1-infected individuals.

  2013cites this paper
• MIGRAs: are they the new IGRAs? Development of monokine-amplified IFN-γ release assays.

  2012cites this paper
• High plasma CXCL10 levels are associated with HCV-genotype 1, and higher insulin resistance, fibrosis, and HIV viral load in HIV/HCV coinfected patients.

  2012cites this paper
• Genomics and HCV infection: progression of fibrosis and treatment response.

  2012cites this paper
• From the Field Syphilis Negatively Influences the Response to Hepatitis C Virus Treatment in an HIV-Infected Patient

  2012cites this paper
• Chemokine receptor expression in peripheral blood monocytes from patients with neovascular age-related macular degeneration.

  2012cites this paper
• Complete Definition of Immunological Correlates of Protection and Clearance of Hepatitis C Virus Infection: A Relevant Pending Task for Vaccine Development

  2012cites this paper
• Case Report From the Field Syphilis Negatively Influences the Response to Hepatitis C Virus Treatment in an HIV-Infected Patient

  2012cites this paper
• IFN/Ribavirin therapy during HCV-HIV-1 co-infection

  2012cites this paper
• Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection.

  2012cites this paper
• Cases From the Field Syphilis Negatively Influences the Response to Hepatitis C Virus Treatment in an HIV-Infected Patient 134

  2012cites this paper
• Information methods for model selection in linear mixed effects models with application to HCV data

  2011cites this paper
• CXCR3 Expression Elevated on Peripheral CD8+ Lymphocytes from HIV/HCV Coinfected Individuals

  2011cites this paper
• Plasma interferon-gamma-inducible protein-10 can predict virologic response to hepatitis C virus therapy in HIV/HCV-coinfected patients with HCV genotype 1.

  2010cites this paper
• Dipyrithione inhibits IFN-γ-induced JAK/STAT1 signaling pathway activation and IP-10/CXCL10 expression in RAW264.7 cells

  2010cites this paper
• Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting.

  2010cites this paper
• IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV

  2010influential citation
• HIV-1/HCV co infection : Immunity and viral dynamics

  2010cites this paper
• Paramètres immunologiques dans les hépatites virales chroniques: évaluation des réponses lymphocytaires spécifiques CD4+ et CD8+ au cours de l'hépatite virale chronique C

  2009cites this paper
• Molecular characterization, expression and functional analysis of goldfish (Carassius aurutus L.) interferon gamma.

  2009cites this paper
• Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection.

  2008cites this paper
• Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis

  2008cites this paper